Abstract
Background: The benzoxazepine JL13 is an analogue of the clozapine family of antipsychotic agents which target the 5-HT2A receptor, and has showed promise as an atypical antipsychotic agent. Based on the dearth of clinically effective anti-psychotic agents available, we sought to design and chemically synthesize additional analogues.
Methods: Structure function analysis was conducted using state of art computational methods, which were designed to highlight new candidates for chemical synthesis. Efficient syntheses were then conducted and the products screened for affinity to the receptor.
Results: Among many new analogues prepared, an aza analogue demonstrated seventeen times greater affinity for the receptor than JL13.
Conclusion: An efficient synthetic route to an aza-analogue of JL13 was developed and will allow rapid modifications of the core and synthesis of related libraries.
Keywords: 5HT receptor, antipsychotic, clozapine, diazepine, JL13, synthesis.
Central Nervous System Agents in Medicinal Chemistry
Title:Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13
Volume: 17 Issue: 3
Author(s): Enrico Mongeau, Gengyang Yuan, Zachary Minden, Scott Waldron, Raymond Booth, Daniel Felsing, Mary J. Ondrechen and Graham B. Jones*
Affiliation:
- Clinical and Translational Science Institute, Tufts University Medical Center, 800 Washington Street, Boston, MA 02111,United States
Keywords: 5HT receptor, antipsychotic, clozapine, diazepine, JL13, synthesis.
Abstract: Background: The benzoxazepine JL13 is an analogue of the clozapine family of antipsychotic agents which target the 5-HT2A receptor, and has showed promise as an atypical antipsychotic agent. Based on the dearth of clinically effective anti-psychotic agents available, we sought to design and chemically synthesize additional analogues.
Methods: Structure function analysis was conducted using state of art computational methods, which were designed to highlight new candidates for chemical synthesis. Efficient syntheses were then conducted and the products screened for affinity to the receptor.
Results: Among many new analogues prepared, an aza analogue demonstrated seventeen times greater affinity for the receptor than JL13.
Conclusion: An efficient synthetic route to an aza-analogue of JL13 was developed and will allow rapid modifications of the core and synthesis of related libraries.
Export Options
About this article
Cite this article as:
Mongeau Enrico , Yuan Gengyang , Minden Zachary , Waldron Scott, Booth Raymond , Felsing Daniel, Ondrechen J. Mary and Jones B. Graham*, Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13, Central Nervous System Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1871524917666170426123607
DOI https://dx.doi.org/10.2174/1871524917666170426123607 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From the Editors Perspective: Aquaporins to Apoptosis
Current Neurovascular Research Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Nanoparticles in the Pharmaceutical Industry and the Use of Supercritical Fluid Technologies for Nanoparticle Production
Current Drug Delivery Pituitary Adenylate Cyclase Activating Polypeptide in Animal Models of Neurodegenerative Disorders - Implications for Huntington and Parkinsons Diseases
Letters in Drug Design & Discovery Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Systemic Fungal Infections Caused by Aspergillus Species: Epidemiology, Infection Process and Virulence Determinants
Current Drug Targets Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Frontal Lobe Synaptic Plasticity in Development and Disease: Modulation by the Dopamine D1 Receptor
Current Pharmaceutical Design Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Actual Knowledge of Systemic Inflammation Reaction During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Synthetic Approaches to the 2006 New Drugs
Mini-Reviews in Medicinal Chemistry Deep Learning in Disease Diagnosis: Models and Datasets
Current Bioinformatics Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets The Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Inhibits HIV-1 Replication by Targeting the Enzyme Reverse Transcriptase
Current HIV Research Compared Chemical Activity and Effects on Cell Viability of Various Antioxidant Compounds
Current Analytical Chemistry Whole body vibration training improves walking performance of stroke patients with knee hyperextension: a randomized controlled pilot study
CNS & Neurological Disorders - Drug Targets Alcoholic Liver Disease: from CYP2E1 to CYP2A5
Current Molecular Pharmacology